Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 9, 2010, Pages 785-788

  Suslova, I M ^a   Theodoropoulos, D S ^b,c   Cullen, N A M ^c   Tetarnikova, M K ^d   Tetarnikov, A S ^d   Kolchak, Nikolai A ^a  

^a Omsk State Pedagogic University   (Russian Federation)

^b Allergy Associates of La Crosse and Fransiscan Skemp Hospital Mayo Health System   (United States)

^c Institute of Medical Immunology   (Greece)

^d NONE

Author keywords

Autoimmune diseases; Hematopoietic stem cell transplantation; HSCT; Pemphigus

Indexed keywords

ALEMTUZUMAB; DESMOGLEIN 1 ANTIBODY; RAPAMYCIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; BONE MARROW CELL; CASE REPORT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HUMAN; NONMYELOABLATIVE CONDITIONING; PEMPHIGUS VULGARIS; REMISSION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PEMPHIGUS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 78649416019     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. KORMAN NJ. Pemphigus. J Acad Dermatol 1988; 18: 1219-1238.
2. LEVER WF, SCHAUMBER-LEVER G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtaine in 63 patients between 1961 and 1975. Arch Dermatol 1977; 113: 1236.
3. KORMAN NJ, EYRE RW, KLAUS-KOVTUN V, STANLEY JR. Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceous and pemphigus vulgaris. N Engl J Med 1989; 321: 631-635.
4. ANHALT GJ, LABIB RS, VOORHEES JJ, BEALS TF, DIAZ LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Eng J Med 1982; 306: 1189-1196.
5. HAYAG MV, COHEN JA, KERDEL FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1065-1069.
6. JUDD KP, LEVER WF. Correlation of antibodies in skin and serum with disease severity in pemphigus. Arch Dermatol 1979; 115: 428-432.
7. MOY R, JORDON RE. Immunopathology in pemphigus. Clin Dermatol 1983; 1: 72-82.
8. KORMAN NJ. Pemphigus. Immunodermatology 1990; 8: 689-700.
9. KOWALCZYK AP, ANDERSON JE, BORGWARDT JE, HASHIMOTO T, STANLEY JR, GREEN KJ. Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1. J Invest Dermatol 1995; 105: 147-152.
10. DING X, AOKI V, MASCARO JM JR, LOPEZ-SWIDERSKI A, DIAZ LA, FAIRLEY JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 592-596.
11. OYAMA Y, PARKER ER, BRIEVA J, GUITART J, STATKUTE L, VERDA L, BURT RK. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceous. Bone Marrow Transplant 2004; 34: 1097-1098.
12. NOLLET F, BILLIET J, SELLESLAG D, CRIEL A. Standardization of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 2001; 28: 511-518.
13. VANIKAR AV, MODI PR, PATEL RD, KANODIA KV, SHAH VR, TRIVEDI VB, TRIVEDI HL. Hematopoietic stem cell transplantation in autoimmune diseases: the Ahmedabad experience. Transplant Proc 2007; 39: 703-708.
14. BATTAGLIA M, STABILINI A, MIGLIAVACCA B, HOREJS-HOECK J, KAUPPER T, RONCAROLO MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-8347.
15. COENEN JJ, KOENEN HJ, VAN RIJSSEN E, KASRAN A, BOON L, HILBRANDS LB, JOOSTEN I. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007; 39: 537-545.